Company profile
Frontier Medicines Corporation
Privately held: no public share price (Private biotech — NOT the airline Frontier Group Holdings (ULCC), which an automated name match wrongly proposed. $255M raised incl. an $80M Series C (2024); no listing as of Aug 2026. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.cbinsights.com/company/frontier-medicines/financials]) · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.